considerably biased to a certain point. He ran YMI's Mayo Clinic trial
There's not a lot of editorial comment in that letter. And on balance, I wouldn't say this report is necessarily bullish for YMI either - no particular reason to assume their results will be dramatically better. And if lack of durability proves to be a class effect, then the whole market is smaller than people have been assuming. Likely the rebound on discontinuation will at the very least prove to be a class effect.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.